Trastuzumab brengitecan
SystImmune's HER2 ADC, sharing its payload with iza-bren, now in a 1,450-patient trial to replace Kadcyla after surgery.
Phase 1 (ESMO 2025; Lancet-family 2026): responses in HER2-positive and HER2-low breast cancer. Phase 3 versus T-DM1 in residual disease after neoadjuvant therapy (~1,450 patients) enrolling in China; the same setting DESTINY-Breast05 has just redefined with T-DXd.
Trastuzumab brengitecan (BL-M07D1) carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
Compare all products across the US, EU, UK, Japan, China and Australia →
- Feb 2025Filing / dealChina
Phase 3 vs T-DM1 in residual disease registered (NCT06830889) source
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Trastuzumab brengitecan" OR ABSTRACT:"Trastuzumab brengitecan" OR TITLE:"BL-M07D1" OR ABSTRACT:"BL-M07D1" OR TITLE:"T-Bren" OR ABSTRACT:"T-Bren") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Trastuzumab brengitecan, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductTrastuzumab duocarmazine
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- ProductTrastuzumab rezetecan
Shares Topoisomerase-I inhibitors (and ADC payloads), HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- IdeaTwo-target antibody drugs to close the antigen escape route
Shares SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
- IdeaCan T-DXd alone cure early HER2-positive disease?
- ProductARX788
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- PersonBob T. Li
Shares HER2, Antibody-drug conjugate (ADC).
- TermT030 (belotecan derivative)
Shares Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
- PersonJoaquín Arribas
Shares HER2, HER2-positive breast cancer.